

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1 (currently amended): An isolated nucleic acid molecule ~~which comprising~~ comprising ~~[[es]]~~ a polynucleotide having at least about ~~[[80%]]~~ 90% sequence identity to ~~[[a)]]~~ a DNA molecule encoding an FGF-19 polypeptide comprising amino acid residues from ~~about-1 or about-23 to about-216 of Figure 2 (SEQ ID NO:2), or (b) the complement of the DNA molecule of (a),~~ wherein the FGF-19 polypeptide reduces total body mass in an individual, reduces fat in an individual, reduces level of triglycerides and free fatty acids in an individual, increases metabolic rate of an individual, induces leptin release from an adipocyte cell, or decreases glucose uptake in an adipocyte cell.

2 (currently amended): The isolated nucleic acid molecule of Claim 1 comprising nucleotides from ~~about-464 or about-530 to about-1111 of Figure 1 (SEQ ID NO:1).~~

3 (previously presented): The isolated nucleic acid molecule of Claim 1 comprising the polynucleotide sequence of Figure 1 (SEQ ID NO:1).

4 (currently amended): The isolated nucleic acid molecule of Claim 1 comprising a polynucleotide sequence that encodes amino acid residues from ~~about-1 or about-23 to about-216 of Figure 2 (SEQ ID NO:2).~~

5 (currently amended): An isolated nucleic acid molecule comprising a polynucleotide having at least about ~~[[80%]]~~ 90% sequence identity to ~~[[a)]]~~ a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA deposited with the ATCC on November 21, 1997 under ATCC Deposit No. 209480 (DNA49435-1219), ~~or (b) the complement of the DNA molecule of (a),~~ wherein the mature polypeptide reduces total body mass in an individual, reduces fat in an individual, reduces level of triglycerides and free fatty acids in an individual, increases metabolic rate of an individual, induces leptin release from an adipocyte cell, or decreases glucose uptake in an adipocyte cell.

6 (previously presented): The isolated nucleic acid molecule of Claim 5 comprising a polynucleotide encoding the same mature polypeptide encoded by the human protein cDNA deposited with the ATCC on November 21, 1997 under ATCC Deposit No. 209480 (DNA49435-1219).

7 (currently amended): An isolated nucleic acid molecule comprising a polynucleotide having at least about ~~[[80%]]~~90% sequence identity to ~~[[a)]]~~ the full-length polypeptide coding sequence of the human protein cDNA deposited with the ATCC on November 21, 1997 under ATCC Deposit No. 209480 (DNA49435-1219), ~~or (b) the complement of the coding sequence of (a),~~ wherein the polypeptide encoded by the human protein cDNA reduces total body mass in an individual, reduces fat in an individual, reduces level of triglycerides and free fatty acids in an individual, increases metabolic rate of an individual, induces leptin release from an adipocyte cell, or decreases glucose uptake in an adipocyte cell.

8 (original): The isolated nucleic acid molecule of Claim 7 comprising the full-length polypeptide coding sequence of the human protein cDNA deposited with the ATCC on November 21, 1997 under ATCC Deposit No. 209480 (DNA49435-1219).

9 (currently amended): An isolated nucleic acid molecule encoding an FGF-19 polypeptide comprising a polynucleotide that hybridizes under stringent conditions to the complement of a polynucleotide that encodes amino acid residues from ~~about-1 or about-23 to about-216~~ of Figure 2 (SEQ ID NO:2, wherein stringent hybridization conditions comprise 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C, and wherein the FGF-19 polypeptide reduces total body mass in an individual, reduces fat in an individual, reduces level of triglycerides and free fatty acids in an individual, increases metabolic rate of an individual, induces leptin release from an adipocyte cell, or decreases glucose uptake in an adipocyte cell.

10 (currently amended): The isolated nucleic acid molecule of Claim 9, wherein the polynucleotide that encodes amino acids from ~~about-1 or about-23 to about-216~~ of Figure 2 (SEQ ID NO:2) comprises nucleotides from ~~about-464 or about-530 to about-1111~~ of Figure 1 (SEQ ID NO:1).

11-13 (canceled)

14 (currently amended): A vector comprising the nucleic acid molecule of any of Claims 1, 4, 5, or 6 [[or 4]].

15 (original): The vector of Claim 14, wherein said nucleic acid molecule is operably linked to control sequences recognized by a host cell transformed with the vector.

16 (original): A nucleic acid molecule deposited with the ATCC under accession number 209480 (DNA49435-1219).

17 (original): A host cell comprising the vector of Claim 14.

18 (original): The host cell of Claim 17, wherein said cell is a CHO cell.

19 (original): The host cell of Claim 17, wherein said cell is an *E. coli*.

20 (original): The host cell of Claim 17, wherein said cell is a yeast cell.

21 (original): A process for producing an FGF-19 polypeptide comprising culturing the host cell of Claim 17 under conditions suitable for expression of said FGF-19 polypeptide and recovering said FGF-19 polypeptide from the cell culture.

22-23 (cancelled)

24 (currently amended): The isolated nucleic acid of Claim 1, wherein the polynucleotide has at least about 95% sequence identity to (a) a DNA molecule encoding an FGF-19 polypeptide comprising amino acid residues from ~~about~~-1 or ~~about~~-23 to ~~about~~-216 of Figure 2 (SEQ ID NO:2), or (b) the complement of the DNA molecule of (a).

25 (currently amended): The isolated nucleic acid of Claim 1, wherein the polynucleotide has at least about 99% sequence identity to (a) a DNA molecule encoding an FGF-19 polypeptide comprising

amino acid residues from ~~about~~-1 or ~~about~~-23 to ~~about~~-216 of Figure 2 (SEQ ID NO:2), or (b) the complement of the DNA molecule of (a).

26 (currently amended): The isolated nucleic acid molecule of Claim 1 consisting of a polynucleotide sequence that encodes amino acid residues from ~~about~~-1 or ~~about~~-23 to ~~about~~-216 of Figure 2 (SEQ ID NO:2).

27 (currently amended): The isolated nucleic acid molecule of Claim 1 comprising a polynucleotide sequence that encodes amino acid residues from ~~about~~ any of 17 to 27 to ~~about~~-216 of Figure 2 (SEQ ID NO:2).

28-33 (cancelled)

34 (previously presented): A process for producing an FGF-19 polypeptide comprising culturing a host cell comprising a nucleic acid molecule deposited with the ATCC under accession number 209480 (DNA49435-1219) under conditions suitable for expression of said FGF-19 polypeptide and recovering said FGF-19 polypeptide from the cell culture.

35 (previously presented): A composition comprising the polynucleotide of any of Claims 1, 4, 5, 7, or 9.

36 (previously presented): The host cell of Claim 17, wherein said cell is a mammalian cell.

37 (new): An isolated nucleic acid molecule encoding an FGF-19 polypeptide comprising a polynucleotide that hybridizes under stringent conditions to the complement of the full-length polypeptide coding sequence of the human protein cDNA deposited with the ATCC on November 21, 1997 under ATCC Deposit No. 209480 (DNA49435-1219), wherein stringent hybridization conditions comprise 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C, and wherein the FGF-19 polypeptide reduces total body mass in

an individual, reduces fat in an individual, reduces level of triglycerides and free fatty acids in an individual, increases metabolic rate of an individual, induces leptin release from an adipocyte cell, or decreases glucose uptake in an adipocyte cell.

38 (new): A vector comprising the nucleic acid molecule of Claims 9 or 37.

39 (new): The vector of Claim 38, wherein said nucleic acid molecule is operably linked to control sequences recognized by a host cell transformed with the vector.

40 (new): A host cell comprising the vector of Claim 39.

41 (new): The host cell of Claim 40, wherein said cell is a CHO cell.

42 (new): The host cell of Claim 40, wherein said cell is an *E. coli*.

43 (new): The host cell of Claim 40, wherein said cell is a yeast cell.

44 (new): The host cell of Claim 40, wherein said cell is a mammalian cell.

45 (new): A process for producing an FGF-19 polypeptide comprising culturing the host cell of Claim 40 under conditions suitable for expression of said FGF-19 polypeptide and recovering said FGF-19 polypeptide from the cell culture.

46 (new): An isolated nucleic acid encoding a chimeric molecule, wherein the isolated nucleic acid comprising (a) a nucleic acid of any of claims 1, 5, 7, 9, or 37, fused to (b) a polynucleotide encoding a heterologous polypeptide.